In this article, we will be taking a look at the 11 best future stocks to buy now.

Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars. These patterns have made some wonder if regulators will curb their expansion in 2025 or if the government will give them more leeway. Bradley Tusk, a venture capitalist, spoke on CNBC about the industries that are predicted to grow in 2025 and how legislative changes may impact investments in these booming sectors.

We would probably see a more hospitable environment for M&A activity and new technology in fintech, healthcare tech, and energy, he said, even though some of the regulations on big tech might remain in place. As a result, the different elements are lining up nicely, particularly in the venture capital industry. Although there hasn’t been much activity there in recent years, things are finally beginning to improve.

Tusk expressed concerns over the government’s ability to ensure safety and competitiveness in tech, citing Internet 2.0 as an example of delayed regulation. He warned that without strong federal leadership, states might adopt conflicting AI regulations, making compliance difficult for companies.

Despite this, Tusk believes the AI industry will push forward due to heavy investment and ongoing momentum. However, he emphasized that 2025 must be the year AI delivers real-world results—moving beyond hype to generate actual revenue and savings.

Tusk believes the future of crypto looks brighter, expecting more favorable and reasonable regulations under the current administration compared to the past four years under SEC Chair Gary Gensler, who was strongly anti-crypto. While not all legislation will be welcomed, it’s likely to be more balanced.

On fintech, Tusk noted the previous administration was heavy-handed with regulations. There’s hope for significant administrative deregulation, but he’s doubtful it will happen if it requires new legislation.

Our Methodology 

For our methodology, we selected the stocks based on their high upside potential and ranked them according to hedge fund sentiment data from Q1 2025, as tracked by the Insider Monkey database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 11 best future stocks to buy now. 

11. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 10 

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best future stocks to buy now. It is transforming cancer care through immunotherapies that activate the body’s natural defenses. Its lead therapy, ANKTIVA (nogapendekin alfa inbakicept), has already been approved by the FDA for treating certain types of bladder cancer. The company is now expanding its approach with a focus on reversing lymphopenia, an immune deficiency often caused by chemotherapy, radiation, or immunotherapy.

In June 2025, the FDA authorized an Expanded Access Program for ANKTIVA under the Cancer BioShield platform, making it the first approved therapy to target treatment-induced lymphopenia in patients with solid tumors who failed standard therapies. At ASCO 2025, data showed that restoring immune health with ANKTIVA, especially when paired with CAR-NK therapy, can significantly improve survival in metastatic pancreatic cancer patients.

Internationally, ImmunityBio, Inc. (NASDAQ:IBRX) is gaining momentum. In July 2025, the UK approved ANKTIVA with BCG for non-muscle invasive bladder cancer (NMIBC), marking its first approval outside the U.S. Additionally, a partnership with Saudi Arabia’s health system will bring the Cancer BioShield platform to the Middle East.

The company is also expanding clinical trials, including a U.S.-based study testing ANKTIVA with PD-1 inhibitors in non-small cell lung cancer (NSCLC), with plans to expand globally. Meanwhile, the business is seeking broader FDA approval for ANKTIVA + BCG in bladder cancer after addressing regulatory hurdles.

By targeting immune collapse caused by cancer treatments, ImmunityBio, Inc. (NASDAQ:IBRX) is introducing a paradigm shift, fighting both cancer and immune dysfunction simultaneously. With FDA designations, strategic global alliances, and promising clinical data, the company is advancing a potentially life-extending new standard in oncology.

10. Cosan S.A. (NYSE:CSAN)

Number of Hedge Fund Holders: 13 

Cosan S.A. (NYSE:CSAN), a Brazilian conglomerate founded in 1936, operates across energy, agribusiness, logistics, oil and gas, and natural gas distribution. Through key subsidiaries like Raízen (bioenergy), Rumo (rail logistics), Compass (natural gas), and Moove (lubricants), the business plays a central role in Brazil’s energy transition by connecting agricultural production to export hubs and investing in cleaner fuels.

In 2025, Cosan S.A. (NYSE:CSAN) strengthened its leadership in regional energy with a landmark move: its subsidiary Edge completed Brazil’s first import of Argentine natural gas via Bolivia. This initiative enhances supply flexibility and promotes energy integration in South America, aligning with Brazil’s cleaner energy goals.

The company also focused on portfolio optimization by divesting non-core assets, including its stake in Vale, while acquiring DIPI Holdings S.A. to boost its logistics platform. A major corporate restructuring streamlined operations and improved investor transparency.

Operationally, Cosan S.A. (NYSE:CSAN) faced a fire at its Moove lubricants plant in Rio de Janeiro. Thanks to an agile, asset-light approach and insurance coverage for repairs, disruptions were minimized, preserving financial stability.

The company continues to invest in sustainable growth. Its joint venture, Raízen, is expanding renewable fuel production, and Rumo is developing efficient agri-export corridors. These efforts reflect Cosan S.A. (NYSE:CSAN)’s broader commitment to decarbonization and energy resilience.

9. BRF S.A. (NYSE:BRFS)

Number of Hedge Fund Holders: 16 

BRF S.A. (NYSE:BRFS), a major global food company headquartered in Brazil, has significantly advanced its international strategy in 2025 through two key developments: a transformative merger with Marfrig Global Foods and major expansions in Saudi Arabia and China.

On May 15, 2025, BRF S.A. (NYSE:BRFS) and Marfrig announced a definitive merger to form MBRF Global Foods Company S.A., aiming to become a global protein industry leader. The merger, pending shareholder approval on August 5, is expected to deliver R$805 million (approx. $141 million) in annual synergies through cost optimization and operational integration. The new entity is also exploring redomiciliation and a potential U.S. listing to enhance valuation and liquidity, positioning it among the best growth stocks in the sector.

Simultaneously, the corporation is expanding its international presence. In Saudi Arabia, it began constructing a $160 million processed-foods facility in Jeddah, its third plant in the country and seventh in the Middle East. Set to open in 2026 with a 40,000-tonne annual capacity, the factory supports Saudi food security goals and strengthens BRF S.A. (NYSE:BRFS)’s position in the halal market.

In China, the company completed the acquisition of a processed-foods plant in Henan Province, doubling its production capacity in the region to 60,000 tonnes. This move enables BRF S.A. (NYSE:BRFS) to better serve local consumers and reduce exposure to global supply chain disruptions.

8. CG Oncology, Inc. (NASDAQ:CGON)

Number of Hedge Fund Holders: 24 

CG Oncology, Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company developing bladder-sparing immunotherapies, with a primary focus on cretostimogene grenadenorepvec, a targeted oncolytic virus therapy for bladder cancer. Their lead program targets high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), an area with limited options beyond invasive surgery.

Recent data from the Phase 3 BOND-003 trial, presented in June 2025, revealed a 75.5% complete response rate, with 42.3% of patients maintaining that response at 24 months. Impressively, 97.3% remained free of progression to muscle-invasive disease, and 91.6% avoided cystectomy. The therapy was also well-tolerated, with no grade 3 or higher treatment-related adverse events reported.

Cretostimogene stands out as a potential new standard for NMIBC, offering durable cancer control without surgery and preserving patients’ quality of life. Its promising results have sparked interest in combining it with other therapies like pembrolizumab, further expanding its therapeutic potential.

CG Oncology, Inc. (NASDAQ:CGON) continues to expand its clinical footprint with trials targeting both BCG-naïve and previously treated patients. A Biologics License Application (BLA) is expected soon, supported by strong Phase 2 combination data published in Nature Medicine. The business is also offering expanded access programs, broadening patient reach before full regulatory approval.

7. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Number of Hedge Fund Holders: 27 

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics for diseases with high unmet medical needs. Its proprietary TRiM platform enables precise silencing of disease-causing genes, positioning the company as a frontrunner in gene-targeted treatments and one of the best growth stocks in the biotech space.

In July 2025, the company achieved a major milestone, a $100 million payment from Sarepta Therapeutics as part of a broader licensing and collaboration deal. The agreement includes clinical and preclinical RNAi candidates, offering the corporation up to $10 billion in potential milestone and royalty payments. This collaboration provides strong financial backing and external validation of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s RNAi technology.

The business is making significant progress in the late-stage development of its cardiometabolic pipeline. In July 2025, the company initiated the Phase 3 YOSEMITE study for zodasiran in homozygous familial hypercholesterolemia. It also completed enrollment for several Phase 3 trials (SHASTA-3, SHASTA-4, and MUIR-3) evaluating plozasiran for severe hypertriglyceridemia and rare lipid disorders. Plozasiran’s NDA has been accepted by the FDA, with a potential approval date of November 18, 2025.

These developments underscore Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s momentum in bringing RNAi therapies to market. Positive Phase 3 results, including significant reductions in triglycerides and pancreatitis, highlight the strong efficacy of its treatments.

6. Denali Therapeutics Inc. (NASDAQ:DNLI)

Number of Hedge Fund Holders: 31 

Denali Therapeutics Inc. (NASDAQ:DNLI) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, focused on developing therapies for neurodegenerative and lysosomal storage disorders. Its proprietary TransportVehicle (TV) technology enables the delivery of biologics across the blood-brain barrier, targeting neurological symptoms often left untreated by conventional therapies.

In July 2025, the company achieved a major milestone as the FDA accepted and granted Priority Review for its Biologics License Application (BLA) for tividenofusp alfa, a novel enzyme replacement therapy for Hunter syndrome (MPS II). This designation highlights the urgent medical need and sets a PDUFA decision date of January 5, 2026, opening the door for potential approval and launch by early 2026.

Tividenofusp alfa is a first-in-class brain-penetrant enzyme therapy designed to overcome a key limitation of current treatments, which do not reach the brain and fail to address neurological symptoms. In clinical trials, Denali Therapeutics Inc. (NASDAQ:DNLI)’s therapy demonstrated effective delivery of the missing enzyme to the central nervous system, showing promise for addressing both somatic and neurological aspects of Hunter syndrome.

If approved, this therapy would not only offer new hope for patients with Hunter syndrome but also validate the corporation’s TV platform, accelerating the development of additional treatments for other disorders like Sanfilippo syndrome (DNL126) and other central nervous system diseases. The milestone marks a transformative moment for Denali Therapeutics Inc. (NASDAQ:DNLI), potentially expanding its leadership in next-generation rare disease therapies.

5. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Number of Hedge Fund Holders: 31 

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands fifth on our list among the best future growth stocks to buy now. It is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies for rare endocrine diseases and tumors. Its lead candidate, PALSONIFY (paltusotine), is an investigational once-daily oral somatostatin receptor type 2 (SST2) agonist being developed for acromegaly.

At the July 2025 ENDO Annual Meeting, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented long-term data from the open-label extensions of its PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, showing that PALSONIFY maintained durable IGF-1 control, reduced symptom burden, and had a consistent safety profile. These findings strengthen its case as a next-generation oral alternative to current injectable therapies, which are the standard of care for acromegaly.

The company is now approaching a major inflection point, with a PDUFA date set for late 2025, potentially making PALSONIFY the first oral treatment approved for acromegaly. This would represent a significant shift in disease management and convenience for patients.

Beyond PALSONIFY, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is advancing other pipeline programs, including Atumelnant, aimed at treating congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, as well as several early-stage endocrine disorder therapies. The corporation also expanded its workforce in July 2025, granting equity awards to 46 new employees to support future growth.

4. Apogee Therapeutics, Inc. (NASDAQ:APGE)

Number of Hedge Fund Holders: 36 

Apogee Therapeutics, Inc. (NASDAQ:APGE) is a clinical-stage biotech company developing novel antibody-based therapies for inflammatory and immunology (I&I) conditions, including atopic dermatitis (AD), asthma, eosinophilic esophagitis, and COPD. Using advanced antibody engineering, the company aims to improve efficacy and extend dosing intervals, addressing major unmet needs in these large markets.

In July 2025, Apogee Therapeutics, Inc. (NASDAQ:APGE) reported positive 16-week results from its Phase 2 APEX trial of APG777, an anti-IL-13 antibody for moderate-to-severe AD. The data demonstrated strong efficacy and safety, positioning APG777 as a potential best-in-class therapy with differentiated dosing advantages. The company held a webcast on July 7 to discuss these promising results, which support advancing the candidate to later-stage trials.

The business’s pipeline also includes APG990, which showed favorable pharmacokinetics in Phase 1 trials, suggesting it could be administered as infrequently as every three to six months. The combination of APG777 and APG990 reflects Apogee Therapeutics, Inc. (NASDAQ:APGE)’s strategy to deliver long-acting, highly effective treatments for chronic inflammatory diseases.

3. Viking Therapeutics, Inc. (NASDAQ:VKTX)

Number of Hedge Fund Holders: 41 

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company developing treatments for metabolic and endocrine disorders, including obesity, NASH, and rare diseases like X-linked adrenoleukodystrophy (X-ALD). Its lead candidate, VK2735—a dual GLP-1/GIP receptor agonist- is now in Phase 3 VANQUISH trials for obesity and obesity with type 2 diabetes, following strong Phase 1 and 2 results demonstrating significant weight loss and safety, making it one of the best growth stocks in the biotech sector.

Viking Therapeutics, Inc. (NASDAQ:VKTX) has also completed enrollment in a Phase 2 trial for an oral version of VK2735, with top-line results expected in the second half of 2025. If successful, the oral formulation could offer a more convenient alternative to injectable obesity drugs.

The company is further expanding its pipeline with a novel amylin agonist program aimed at metabolic disorders, expecting to file an IND by Q4 2025. Additionally, VK2809, a thyroid hormone receptor beta agonist for NASH, has shown positive Phase 2b results. The business is also advancing VK0214 for X-ALD and other programs targeting lipid metabolism.

With a robust pipeline and $808 million in cash (as of June 2025), Viking Therapeutics, Inc. (NASDAQ:VKTX) is well-positioned to fund upcoming milestones. The Phase 3 VK2735 trials and pending oral trial results are key near-term catalysts.

2. Vaxcyte, Inc. (NASDAQ:PCVX)

Number of Hedge Fund Holders: 45 

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotech company focused on developing next-generation pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD). The company recently reported positive topline results from its Phase 2 study of VAX-24 in infants. The 24-valent vaccine candidate met all primary endpoints for safety, tolerability, and immunogenicity compared to Pfizer’s Prevnar 20, with robust immune responses and no serious vaccine-related adverse events. Full data following the fourth booster dose are expected by year-end 2025.

Building on this progress, Vaxcyte, Inc. (NASDAQ:PCVX) is advancing VAX-31, a 31-valent PCV targeting broader strain coverage, approximately 94% in U.S. children and 95% in adults. The final stage of its infant Phase 2 trial is underway, with topline results expected by mid-2026. Adult Phase 3 trials are set to begin in mid-2025. VAX-31 has received FDA Breakthrough Therapy designation for adults and investigational approvals for pediatric use, highlighting its potential to address significant unmet medical needs.

The business also unveiled VAX-XL, its third-generation PCV candidate offering the broadest coverage yet, signaling continued innovation in its pipeline. To support commercialization, Vaxcyte, Inc. (NASDAQ:PCVX) is constructing a manufacturing facility at Lonza, expected to be operational by early 2026. Its strong cash reserves of approximately $3 billion provide the necessary funding for R&D and scale-up.

Strategically, the corporation is aligning clinical, regulatory, and manufacturing efforts to become a leader in the global pneumococcal vaccine market. The recent appointment of Dr. Olivier Brandicourt, former CEO of Sanofi, to its board reinforces this vision with deep commercial expertise.

1. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Number of Hedge Fund Holders: 55 

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), based in Novato, California, focuses on developing therapies for rare and ultra-rare genetic diseases and tops our list for being one of the best growth stocks. The company’s portfolio includes commercial products and a strong late-stage pipeline targeting high-need conditions such as Sanfilippo syndrome type A, osteogenesis imperfecta, Angelman syndrome, and glycogen storage diseases.

A key recent development was the FDA’s Complete Response Letter (CRL) on July 11, 2025, for the company’s Biologics License Application for UX111, a gene therapy for Sanfilippo syndrome type A. While the FDA highlighted chemistry, manufacturing, and controls (CMC) issues, it also recognized the robust clinical and biomarker data, affirming the therapy’s efficacy. The business intends to resolve the CMC concerns and resubmit the application, expecting a six-month review.

Beyond UX111, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is advancing other promising therapies. UX143, targeting osteogenesis imperfecta, is progressing toward final analysis after a Phase 3 study. GTX-102, for Angelman syndrome, recently received the FDA Breakthrough Therapy designation, indicating its potential for accelerated development.

The corporation’s strategy is notable for its modality-agnostic approach, leveraging gene therapies, monoclonal antibodies, and antisense oligonucleotides. This diversified platform reduces regulatory risk while maximizing impact across several rare disorders.

Adding to its momentum, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) recently gained Health Canada approval to expand the use of Evkeeza to infants as young as six months with homozygous familial hypercholesterolemia (HoFH), enhancing its commercial reach.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.